Oramed Pharmaceuticals has licensed the product to EnteraBio in 2010, under which Oramed is eligible to get 3% royalties plus a small holding in the company.
The trial involved 12 healthy volunteers and was at the Hadasah Medical Center in Jerusalem.
The results from the Phase 1 trial supports the continued development of Entera’s oral osteoporosis drug.